Thymosin alpha-1
What it is & what research shows
Study example availableThymosin alpha-1 is listed as a peptide in the immune & antimicrobial section of this catalog. Also indexed as thymalfasin, thymosin α1. A source-verified explanation of its mechanism and uses has not yet been completed here; the catalog category is not evidence of benefit.
One selected study: An open-label randomized trial examined thymosin alpha-1, survival and immune-cell changes in severe liver disease. 73 patients with hepatitis B-related acute-on-chronic liver failure, 35 receiving thymosin alpha-1 and 38 standard care alone. Thymosin alpha-1 added to standard medical therapy; dose, route and treatment duration were not stated in the abstract. The authors reported higher 90-day transplant-free survival, fewer regulatory T-cell subsets and moderated late inflammatory responses. The abstract did not provide absolute survival rates or effect uncertainty. Abstract-based assessment of a small, unblinded disease-specific trial. It does not establish generic immune enhancement in healthy people; regimen and detailed safety could not be assessed. [2.1]
Sources & reading scope
- [2.1] Thymosin α1 improves the outcomes of patients with hepatitis B virus-related acute-on-chronic liver failure by restoring immune balance.Human · Abstract summarized · not a full-paper review
Evidence summarized on PED Evidence
1 completed summaries
1 human-study reports
1 randomized-trial candidates
0 safety-topic reports
More about Thymosin alpha-1: identity, safety & reference details
Also known as thymalfasin · thymosin α1
Start with the research
An outcome-specific synthesis has not been prepared for this compound. This is a coverage gap, not evidence that it has no effect.
Open studies and trial records- Uses & research
Uses have not been independently checked for this profile. Browse the original studies to see the conditions and populations investigated.
- Known half-life
No source-verified value in this profile yet. A treatment schedule or duration of an effect is not a drug half-life.
Half-life describes how quickly the measured drug concentration falls by half. It does not set a dosing interval.- Evidence & important limits
A catalog entry does not establish effectiveness, safety or approval. Study findings and quality appraisal remain separate.
Safety & evidence boundaries
A compound-specific safety synthesis is not available here yet. Lack of listed adverse effects does not establish safety.
Explore safety questions by system
These are literature filters, not claims that this compound causes each effect. A keyword match is not a confirmed adverse reaction.
Identity, names & formulations
Canonical compound: Thymosin alpha-1 · thymosinalpha1
Searchable names: thymalfasin, thymosin α1
Names share a parent research page. Different esters, salts, routes and brands are not assumed to have the same half-life, indication or exposure.
Combination evidence stays attached to the studied combination. It is not automatically assigned to each ingredient.
Understand the evidence types
Read the model and design first, then the population, outcome and limitations. These categories describe evidence, not a best-compound ranking.
- Randomized human trials
- Compare assigned interventions. Randomization does not by itself establish low bias or relevance to every population.
- Controlled human studies
- Use a comparison group; allocation and confounding still matter.
- Prospective human research
- Follows participants forward. It may be observational or interventional, so this is not a separate quality grade.
- Observational human research
- Describes associations. Confounding can explain differences.
- Case reports and series
- Useful for unusual events and safety signals, not reliable rates or effect sizes.
- Animal research
- Can test biology and function in a living model. Human exposure, benefit and safety remain separate questions.
- Cell and tissue research
- Tests responses in a preparation, including human-derived cells. It is not a human participant trial.
- Mechanistic and computational evidence
- Helps explain or predict a pathway; predictions need experimental and clinical testing.
- Anecdotal reports
- Self-reported experiences can generate questions. Product identity, selection bias and other interventions may be uncontrolled.
Systematic reviews synthesize studies and depend on their quality. Preprint status and abstract versus full-paper reading are separate labels. Citation popularity measures attention, not reliability. A study summary is not a formal quality appraisal.
Study model describes the source. Confidence depends on methods, replication, population and outcome.
Loading compound research…
Thymosin alpha-1 study summaries
Human-first reading order. Intervention candidates are distinguished from background mentions in the library.